Disease relevance of Bay v-3522

• Susceptibility of anaerobic bacteria to BAY v 3522 [1].
• Among the cephalosporins, BAY v 3522 was the most active against gram-positive cocci and cefixime was the most active against gram-negative bacilli; BAY v 3522 was similar in activity to amoxicillin-clavulanate against most species [2].
• In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis [3].
• Bay v 3522 was found to have high activity against Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis, Haemophilus influenzae, anaerobic cocci, Propionibacterium acnes, Clostridium perfringens and fusobacteria [4].
• In addition to being highly active against streptococci (MIC90 = 0.25 micrograms/ml) and methicillin-susceptible staphylococci (MIC90 = 1.0 micrograms/ml), Bay v 3522 was markedly more active than the other cephalosporins against Enterococcus faecalis (MIC90 = 4 micrograms/ml) [5].

High impact information on Bay v-3522

• In vitro activity of BAY v 3522, a new cephalosporin for oral administration [6].
• The protein binding of Bay v 3522 was 45% [7].
• The primary target of Bay v 3522 was penicillin-binding protein 3 [7].
• The stability of Bay v 3522 to hydrolysis by the SHV-1 and TEM-1 enzymes was intermediate to those of cephalexin (least hydrolyzed) and cefaclor, but it was markedly more stable than amoxicillin [7].
• Bay v 3522 was less potent against Gram-negative pathogens, especially nosocomial isolates of Escherichia coli and Klebsiella pneumoniae (MIC90 greater than 64 micrograms/ml), but was active against Haemophilus influenzae, Moraxella (Branhamella) catarrhalis, and beta-lactamase-negative Neisseria gonorrhoeae (MIC90 = 1.0 micrograms/ml0 [5].

Associations of Bay v-3522 with other chemical compounds

• In vitro activity of Bay v 3522, a new cephalosporin, compared with activities of other agents [7].

Gene context of Bay v-3522

• Bay v 3522 was destroyed by TEM-1, SHV-1, TEM-3 and P99 beta-lactamases [8].
• In vitro activity and beta-lactamase stability of the new oral cephalosporin Bay v 3522 [8].

Analytical, diagnostic and therapeutic context of Bay v-3522

• On the basis of these results, BAY v 3522 appears to have an antibacterial activity that warrants further investigation in clinical trials [1].
• When tested against a higher inoculum or using the broth dilution technique, the activity of Bay v 3522 showed little dependence on inoculum size and the bactericidal activity was similar to inhibitory activity in most bacterial groups [4].

References